An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to results of a preliminary clinical trial led by Johns Hopkins Kimmel Cancer Center scientists.
The antibody, called Medi-551, was tested in 15 newly diagnosed patients with multiple myeloma who also received a monthly regimen of lenalidomide and dexamethasone — already approved chemotherapy drugs that are often prescribed to treat multiple myeloma. The scientists are expected to present their findings April 19 at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans (abstract CT102).
Read more at EurekAlert
Act Now to see all current news from John Hopkins Medicine
